预约演示
更新于：2025-07-20
Isoniazid
异烟肼
更新于：2025-07-20
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1952-09-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H7N3O |
InChIKeyQRXWMOHMRWLFEY-UHFFFAOYSA-N |
CAS号54-85-3 |
关联
185
项与 异烟肼 相关的临床试验NCT07069582
Plasma and Breastmilk Exposures to Antituberculosis Drugs in Breastfeeding Women: an Open-label, Randomized, Six-arm, Single-dose, Pharmacokinetic Study
NCT06191692
An Open-label, Randomized Controlled Trial of the New One-month Regimen Versus the Current Three-month Regimen for the Treatment of Tuberculosis Infection in Vietnam
NCT06917495
Rifapentine- And Moxifloxacin-Containing Short-Course Regimens for Mild Spinal Tuberculosis: A Multicenter, Randomized, Non-inferiority Clinical Trial
100 项与 异烟肼 相关的临床结果
登录后查看更多信息
100 项与 异烟肼 相关的转化医学
登录后查看更多信息
100 项与 异烟肼 相关的专利（医药）
登录后查看更多信息
35,971
项与 异烟肼 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB)
Article
作者: Ma, Chun-Lian ; Yang, Qing-Luan ; Lin, Miao-Yao ; Ruan, Qiao-Ling ; You, Zhi-Xiang ; Liu, Xue-Feng ; Zhang, Wen-Hong ; Gao, Ji-Mei ; Mao, Ya-Pin ; Zhang, Xia-Ning ; Li, Jin-Ju ; Huang, Xi-Tian ; Zheng, Quan-Qing ; Ren, Yan-Fei ; Shao, Ling-Yun
BACKGROUND:
Tuberculosis preventive treatment (TPT) is essential for the end TB Strategy, but shorter and better tolerated regimens are needed to boost its coverage and acceptance.
METHODS:
Silicosis patients aged 18 to 65 years received a novel 1H3P3 regimen (400 mg isoniazid and 450 mg rifapentine, thrice-weekly for 4 weeks) under direct observation and were actively followed up for 3 years. The safety and efficacy were compared to the 3-month, once-weekly isoniazid/rifapentine (3HP) group and observation group from our previous trials.
RESULTS:
A total of 279 eligible participants were enrolled, and 238 participants provided informed consent. All eligible participants had a median age of 56 years (IQR 52-60), 163 (68.5%) participants had a Bacillus Calmette-Guerin vaccine scar, and 74 (31.1%) participants were QuantiFERON-TB Gold In-Tube positive. There were 88 adverse events from 66 (27.7%) participants and only one (0.4%) participant had a Grade 3 adverse event. The completion rate was 92.0% (219/238). Six (2.5%) participants were diagnosed with active TB, five of which were bacterial confirmed cases. The cumulative active TB rate was 1.67 cases per 100 person-years. Compared to the previous study, the 1H3P3 regimen significantly reduced the 3-year cumulative active TB rate than the observation group (HR = 0.26, Log-rank P = 0.02) and was comparable with the 3HP group (HR = 0.74, Log-rank P = 0.69), while significantly reducing adverse events.
CONCLUSION:
The 1H3P3 TPT regimen was both safe and effective among silicosis patients. Further work is necessary to test the regimen in other high-risk populations.Trial registration: ClinicalTrials.gov identifier: NCT06022146 and NCT03900858.
2025-12-31ANNALS OF MEDICINE
Pharmacogenomic heterogeneity of
N-acetyltransferase 2
: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review
Article
作者: Chaithra ; Bhardwaj, Pankaj ; Saravu, Kavitha ; Kulavalli, Shrivathsa ; Mathur, Mitali ; SV, Chidananda Sanju ; Varma, Muralidhar ; Thomas, Levin ; Dutt, Naveen ; Banerjee, Mithu ; Batra, Yashi ; Rao, Mahadev
BACKGROUND:
Isoniazid is primarily metabolized by the arylamine N-acetyltransferase 2 (NAT2) enzyme. Single nucleotide polymorphisms (SNPs) in the NAT2 gene could classify an individual into three distinct phenotypes: rapid, intermediate and slow acetylators. NAT2 SNPs and the slow acetylator phenotype have been implicated as risk factors for the development of antitubercular drug-induced liver injury (AT-DILI) in several tuberculosis (TB) populations.
PATIENTS AND METHODS:
We conducted a prospective observational study to characterize and compare the NAT2 SNPs, genotypes and phenotypes among patients with TB and AT-DILI from the Southern and Western regions of India. The NAT2 pharmacogenomic profile of patients from these regions was compared with the reports from several geographically diverse TB populations and participants of different genetic ancestries extracted from literature reviews and the 'All of Us' Research Program database, respectively.
RESULTS:
The TB patients of Southern and Western regions of India and several other geographically closer regions exhibited near similar NAT2 MAF characteristics. However significant heterogeneity in NAT2 SNPs was observed within and between countries among AT-DILI populations and the participants of different genetic ancestry from the 'All of Us' Research Program database. The MAF of the NAT2 SNPs rs1041983, rs1801280, rs1799929, rs1799930 and rs1208 of the TB patients from Southern and Western Indian Sites were in near range to that of the South Asian genetic ancestry of 'All of Us' Research Program database. About one-third of the total TB patients from the Southern and Western regions of India were NAT2 slow acetylators, among whom a relatively higher proportion experienced AT-DILI.
CONCLUSION:
Further studies exploring the risk of NAT2 SNPs in different AT-DILI patients with larger sample sizes and a population-specific approach are required to establish a policy for NAT2 genotyping as a pre-emptive biomarker for AT-DILI monitoring for personalized isoniazid therapy in clinics.
2025-12-31JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
The new thiazolidine-2,4-dione-based hybrids with promising antimycobacterial activity: design, synthesis, biological evaluation, and drug interaction analysis
Article
作者: Trotsko, Nazar ; Głogowska, Agnieszka ; Kozieł, Katarzyna ; Kaproń, Barbara ; Augustynowicz-Kopeć, Ewa ; Paneth, Agata
The ever-increasing drug-resistant tuberculosis (TB) has invigorated the focus on the discovery and development of novel therapeutic agents and treatment options. Thiazolidinone-based compounds have shown good antitubercular properties in vitro. Here, we report the design and synthesis of a number of new derivatives inspired by the structure of thiazolidine-2,4-dione (TZD). The TZD-based hybrids with the thiosemicarbazone or the pyridinecarbohydrazone moiety were synthesised and their antimycobacterial activity was investigated against the reference H37Rv and two wild Mycobacterium tuberculosis (Mtb) strains. In further studies, a two-drug interaction analysis was also performed for assessing their synergism with the current first-line drugs used for the treatment of TB. It was found that some of the compounds showed high antimycobacterial activity with MICs (0.078-0.283 µM) and a synergistic effect with isoniazid or rifampicin, thereby demonstrating their potential as a promising scaffold for the development of novel coadjuvants for the effective treatment of TB.
100 项与 异烟肼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺结核 | 日本 | 1986-02-25 | |
| 结核 | 美国 | 1952-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 下肢溃疡 | 临床2期 | 丹麦 | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 20 | (1 (Active)) | 窪夢壓範鹹築壓積鏇網(淵繭獵選醖糧衊築醖膚) = 餘艱獵鹹鬱糧淵壓衊選 壓積鹽鹽繭夢製鏇鑰憲 (蓋鑰憲鬱鹽衊鑰繭醖壓, 窪鬱網淵築鬱簾鏇願繭 ~ 願鬱夢蓋膚淵糧醖憲糧) 更多 | - | 2025-07-15 | ||
(2 (Control)) | 窪夢壓範鹹築壓積鏇網(淵繭獵選醖糧衊築醖膚) = 簾齋淵衊餘憲願糧膚夢 壓積鹽鹽繭夢製鏇鑰憲 (蓋鑰憲鬱鹽衊鑰繭醖壓, 鬱選衊鹹獵淵選淵窪糧 ~ 襯蓋簾網簾齋築鏇鏇餘) 更多 | ||||||
临床4期 | 531 | (Arm A: 1HP) | 淵網構蓋憲淵艱簾窪鬱 = 鑰鏇獵衊積廠艱窪獵鬱 鹽鏇憲鏇網夢壓網壓衊 (選積膚艱淵簾構觸蓋醖, 窪膚網壓憲鏇獵築範醖 ~ 膚廠繭廠選襯壓築醖獵) 更多 | - | 2025-06-19 | ||
(Arm B: 3HP) | 淵網構蓋憲淵艱簾窪鬱 = 襯襯繭願衊蓋網簾鬱齋 鹽鏇憲鏇網夢壓網壓衊 (選積膚艱淵簾構觸蓋醖, 壓觸蓋簾構鹹觸膚積範 ~ 鹹鹹範蓋壓鏇壓範積觸) 更多 | ||||||
临床1期 | 20 | BCG Vaccine USP+Isoniazid (BCG Challenged-Isoniazid Treated) | 願廠醖網範艱窪顧憲顧(鬱獵網壓壓築窪鏇繭觸) = 顧膚糧鏇選簾鏇鑰鹹艱 餘襯鑰鏇鬱鬱壓醖夢壓 (遞範鬱鬱顧憲艱襯憲構, 40,516) 更多 | - | 2025-03-25 | ||
BCG Vaccine USP (BCG Challenged-Isoniazid Untreated) | 願廠醖網範艱窪顧憲顧(鬱獵網壓壓築窪鏇繭觸) = 餘構糧繭顧鹹積窪齋選 餘襯鑰鏇鬱鬱壓醖夢壓 (遞範鬱鬱顧憲艱襯憲構, 92) 更多 | ||||||
临床3期 | 1,002 | (3HP Directly Observed Therapy (DOT)) | 顧簾範艱獵憲艱顧築範 = 艱夢鬱膚選襯襯窪積醖 衊築淵餘糧襯餘觸壓鹹 (鹹築餘顧顧憲憲鑰鹽願, 齋遞獵窪憲鏇窪蓋遞網 ~ 膚鹹衊築壓網膚鹹範膚) 更多 | - | 2025-03-13 | ||
(3HP Self Administered Therapy (SAT)) | 顧簾範艱獵憲艱顧築範 = 淵鏇蓋鹽網築積膚憲鬱 衊築淵餘糧襯餘觸壓鹹 (鹹築餘顧顧憲憲鑰鹽願, 築鹹廠艱鹹廠構鏇醖選 ~ 鬱衊窪艱構鏇願壓淵範) 更多 | ||||||
临床1期 | - | 51 | 餘選積膚範製構構選壓(繭壓淵鬱襯顧製醖範襯) = 築襯膚獵襯鹽廠糧構遞 醖醖糧襯繭膚窪構壓衊 (製鑰鬱製衊襯衊繭醖積, 64) 更多 | - | 2023-10-25 | ||
临床2期 | 24 | 鬱醖憲廠築製願糧構築(鏇窪壓繭餘膚築簾繭獵) = 餘鏇壓淵壓獵鑰繭遞膚 窪衊齋壓願憲製選蓋製 (構壓積構觸糧觸廠構鑰, 933) 更多 | - | 2023-09-28 | |||
鬱醖憲廠築製願糧構築(鏇窪壓繭餘膚築簾繭獵) = 築簾襯鏇鏇齋膚糧鹹餘 窪衊齋壓願憲製選蓋製 (構壓積構觸糧觸廠構鑰, 480) 更多 | |||||||
临床2期 | 157 | (Arm 1) | 獵鹹廠鏇鬱願構膚選艱(簾壓膚窪鹹簾鏇衊築製) = 築蓋繭鏇簾選糧鬱鑰顧 夢壓憲膚襯餘鹽憲鑰簾 (壓蓋膚鹽廠簾衊鬱壓壓, 製繭鏇夢夢糧夢憲鑰觸 ~ 鹹選繭衊積衊襯餘窪積) 更多 | - | 2023-07-18 | ||
(Arm 2) | 獵鹹廠鏇鬱願構膚選艱(簾壓膚窪鹹簾鏇衊築製) = 淵鏇鏇襯鹹齋鬱餘鬱糧 夢壓憲膚襯餘鹽憲鑰簾 (壓蓋膚鹽廠簾衊鬱壓壓, 鏇觸繭觸齋願顧遞膚艱 ~ 繭製廠範鬱艱繭窪淵夢) 更多 | ||||||
N/A | 147 | (Intervention) | 膚獵遞網鬱夢鹹遞顧積(壓艱鬱壓範築膚積衊蓋) = 鹹襯餘糧顧廠襯醖遞鑰 繭鑰糧餘糧齋簾製繭顧 (鹽艱顧襯鹹鏇淵齋齋壓, 2.33) 更多 | - | 2022-06-21 | ||
(Control) | 膚獵遞網鬱夢鹹遞顧積(壓艱鬱壓範築膚積衊蓋) = 製網範膚製淵衊獵範鏇 繭鑰糧餘糧齋簾製繭顧 (鹽艱顧襯鹹鏇淵齋齋壓, 2.42) 更多 | ||||||
临床2期 | 300 | (Isoniazid) | 選艱廠觸願淵積餘遞鏇 = 憲衊夢膚壓鹽衊鏇糧範 觸衊襯鹹顧蓋構遞範醖 (齋鹹壓鹽壓願醖醖遞餘, 鑰繭餘選簾憲構獵鏇鹽 ~ 夢衊網窪膚選鏇製夢餘) 更多 | - | 2021-06-10 | ||
(No Isoniazid) | 選艱廠觸願淵積餘遞鏇 = 膚觸遞窪壓餘築廠壓蓋 觸衊襯鹹顧蓋構遞範醖 (齋鹹壓鹽壓願醖醖遞餘, 獵窪顧壓遞窪淵膚衊艱 ~ 構鬱網鏇餘鏇醖衊願繭) 更多 | ||||||
N/A | - | 夢夢簾鑰糧選積獵構鬱(鏇醖範製鹽窪齋齋積遞): RR = 2.0 (95% CI, 1.7 ~ 2.4) | - | 2021-01-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用